

# **Assessment of Out of Pocket Expenditure and associated factors for availing COVID-19 vaccination by the beneficiaries in Bengaluru: South India**

**Authors- Dr.Sunil Kumar Dodderi, Dr.Lakshmi H, Dr.Srividya J, Ms.Manjula S, Dr.Swathi R S**

**Affiliations- Dept of Community Medicine, Akash Institute of Medical Sciences and Research Centre, Bengaluru, India**

## **Abstract**

**Background:** Government of India has introduced COVID 19 vaccination in Jan 2021. There are no studies on out of pocket expenditure in COVID- 19 vaccination in India, hence this study was undertaken to estimate the out of pocket expenditure for availing COVID 19 vaccine, to assess the factors associated with out of pocket expenditure for COVID vaccination and adverse events following immunisation.

**Methods:** This is a cross- sectional study conducted during Sep 2021- Dec 2021 of a medical college. A total of 438 study subjects above 18 years fulfilling inclusion and exclusion criteria were studied using probability proportional to population size. Data was collected using interview method by pre-tested semi structured proforma and analysed using descriptive & inferential statistics.

**Results:** The mean direct cost in Government vaccination centre was  $3.24 \pm 6.74$  INR, indirect cost  $809.10 \pm 1076.35$  INR, total cost was  $812.34 \pm 1079.49$  INR. The mean direct cost in private vaccination centre was  $1446.9 \pm 1845.65$  INR, indirect cost  $1140 \pm 1398$  INR and total cost was  $2586.90 \pm 2241.54$  INR.

The mean total cost was OOPE for COVID 19 vaccination was  $852.80 \pm 1128.512$  INR, out of which direct cost was only  $36.17 (\pm 359.20)$ . The higher mean OOPE was found in loss of wages  $670.02$  INR. The factors associated with higher out of pocket expenditure was type of vaccine ( $P=0.031$ ,  $OR=2.141$ ,  $95\% CI=1.07-4.24$ ) occupation of the study subject ( $P=0.000$ ,  $OR=2.043$ ,  $95\% CI= 1.37-3.03$ ), reported stress following vaccination ( $P= 0.018$ ,  $OR=1.72$ ,  $95\%CI=1.098-2.703$ ), adverse event within 48hrs ( $P=0.006$ ,  $OR=2.125$ ,  $95\% CI= 1.248-3.62$ ), received any medication for adverse event ( $P=0.041$ ,  $OR= 1.721$ ,  $95\% CI= 1.022-2.84$ )

**Conclusion:** Majority of the study subjects utilized public facility. The higher mean out of pocket expenditure was for indirect cost loss of wages. This study shows that type of vaccine, occupation of the study subject and adverse event within 48 hrs, had 2 times higher out of pocket expenditure compared to other factors. Among the AEFI, fever was the most common, followed by pain at the injection site and myalgia.

**Keywords:** Health expenditure, Out of pocket expenditure, Covid Vaccination, AEFI, Bengaluru

## **Introduction**

Out of Pocket Expenditures (OOPE) are expenditures directly made by households at the point of receiving health care. This indicates the extent of financial protection available for households towards healthcare payments<sup>1</sup> and is also described as health spending on hospitalization net of reimbursement<sup>2</sup>.

In India, total health expenditure has been estimated to be 3.3% of gross domestic product and OOPE in health care services has been estimated to be 48.8% of the total health expenditure<sup>3</sup>

The government's efforts to improve public healthcare is conspicuous with out-of-pocket expenditure (OOPE) as a share of total health expenditure decreasing to 48.8% in 2017-18 from 64.2% in 2013-14<sup>4</sup>.

Around 90% of all households incurring impoverishing out-of-pocket health spending are already at or below the poverty line. Hence the need of an hour is to exempt the urban slum and poor people, from out-of-pocket health expenditure, with a better health financing policies.<sup>5</sup>

Out-of-pocket expenditure in health care includes traveling costs, loss of wages, cost of registration, consultation, hospital charges, and cost of medications, food and lodging of caregivers<sup>6</sup>. Such out-of-pocket expenditures may lead to catastrophic health expenditures, where in the household has to borrow money or sell their property/assets or when they get contributions from friends/relatives to meet their health care expenses<sup>7</sup>

India began its largest COVID 19 vaccination drive on 16<sup>th</sup> January 2021 to cover health care and frontline workers and scaled up to cover citizens above 45 years of age. The Government of India had selected the priority groups based on the potential availability of vaccines. Individuals with higher risk were given priority. From May 1<sup>st</sup>, 2021, all eligible citizens above the age of 18 years can get the COVID-19 vaccine.<sup>8-10</sup>

In India, Covishield (AstraZeneca's vaccine manufactured by Serum Institute of India) in the month of January, Covaxin (manufactured by Bharat Biotech Limited) in the month of

March, Sputnik - V in the month of April 2021, are the vaccines granted emergency use authorization by the Central Drugs Standard Control Organization<sup>8-10</sup>.

COVID 19 vaccination was provided both at the government and private vaccination centres<sup>8</sup>.

There is lack of data regarding OOPE in COVID 19 vaccination and it affects the economic stability of the household in India. When the expenditure on immunization affects the household, it affects the motivation of for vaccination and hence this research was undertaken and findings of first study on OOPE in COVID 19 vaccination in India will provide the hindsight.

### **Objectives:**

1. To estimate the out of pocket expenditure for availing COVID-19 vaccination in adults above 18 years in Bengaluru, South India.
2. To assess the factors associated with out of pocket expenditure for availing COVID-19 vaccination in adults above 18 years in Bengaluru.
3. To describe the adverse events following immunization after availing COVID-19 vaccination in adults above 18 years in Bengaluru.

### **Material and Methods:**

A cross sectional study was conducted in the urban field practice area, Department of Community Medicine of a medical college, Bengaluru from September 2021 – December 2021. Ethical Clearance was obtained from Institutional ethical committee, Akash Institute of Medical Sciences and Research Centre, Bengaluru, India. The study subjects included COVID -19 fully vaccinated individuals above 18 years of age. In September 2021, Karnataka has the coverage of fully COVID 19 vaccination of 26%, allowable error from prevalence is 20%, the sample size calculated was 273. Considering design effect of 1.5 and 10% additional size it was increased to 438. Respondents fully vaccinated for more than 15 days, who gave informed consent and resided for more than 6 months were enrolled.

The sampling method used is probability proportional to population size, population of urban poor locality was 7688, and number was 11. In each area, an approximate centre was marked, one of the roads was selected randomly by lottery method. After tossing coin one of the sides of road was chosen randomly. After walk through survey, using a currency note, a household

was selected randomly. After interviewing a first household, the next household was selected by tossing the coin until the required sample is met.

The pre-tested tool consisted of both open and closed ended questions of the socio-demographic characteristics, type of vaccine, place of vaccination, side effects following vaccination and medications received. Expenditure incurred for COVID 19 vaccination was captured under two broad categories Direct cost (cost of vaccine, administration charges, cost of medicines, hospital charges) Indirect cost (transportation cost, expenses made for food, loss of wages of the individual and the accompanying person was obtained. A total of 438 study subjects above 18 years fulfilling inclusion and exclusion criteria were studied using probability proportional to population size.

The data collected was entered in MS excel and computed using SPSS 25. Descriptive statistics, inferential statistics logistic regression was used.

## Results

The mean age of the participants  $42.37 \pm 14.41$ . The age range of the participants was 19 to 80. Table 1 describes the socio-demographic characteristics of the study participants.

**Table 1: Socio-demographic profile of study participants**

Age in years	Frequency(n=438)	Percentage (%)
<20	17	3.9
21-30	99	22.6
31-40	94	21.5
41-50	101	23.1
51-60	80	18.3
61-70	40	9.1
71-80	7	1.6
<b>Gender</b>		
Male	245	55.9
Female	193	44.1
<b>Religion</b>		
Hindu	377	86.1
Muslim	61	13.9
<b>Marital Status</b>		
Married	359	82.0
Unmarried	78	17.8
Divorced	1	0.2
<b>Education Status of study subject</b>		

Illiterate	81	18.5
Primary school	35	8.0
Middle school	56	12.8
High school	121	27.6
intermediate/diploma	67	15.3
graduate	63	14.4
professional/post graduate	15	3.4
<b>Occupation of study subject</b>		
Unemployed	163	37.2
unskilled worker	87	19.9
Semi-skilled worker	79	18.0
Skilled	37	8.4
Clerical/shop Farmer	37	8.4
Semi-professional	21	4.8
Professional	14	3.2
<b>Education of Head of household</b>		
Illiterate	88	20.0
Primary school	52	11.9
Middle school	52	11.9
High school	138	31.5
Intermediate/diploma	60	13.7
Graduate	45	10.3
Professional/post graduate	3	0.7
<b>Occupation of Head of household</b>		
Unemployed	7	1.6
Unskilled worker	42	9.6
Semi-skilled worker	112	25.6
Skilled	94	21.5
Clerical/shop Farmer	161	36.8
Semi-professional	12	2.7
Professional	10	2.3
<b>Total income of Household</b>		
<10000	80	18.3
≥10000 – 20,000	220	50.2
≥20000- 30,000	79	18.0
≥30000-40,000	30	6.8
≥40000-50,000	10	2.3
50,000>	19	4.33
<b>Co-morbidity</b>		
Yes	81	18.5
No	357	81.5

Majority of the study participants had hypertension 52 (64.2%), followed by diabetes mellitus 35 (43.2%) and thyroid disorders 7 (8.6%).

**Table 2: Expenditure incurred for direct and indirect expenses for COVID 19 Vaccination**

Direct cost (n=438)	Total Cost (INR)	Mean ± SD (INR)	Median (INR)	Range (INR)	95% CI for Men	
					Lower Berth	Upper Berth
1. Cost of vaccine	13785	31.47(±352.35)	0	0-5000	1.65	64.60
2. Medications	2069	4.72(±41.86)	0	0-500	0.79	8.65
Total	15854	36.17(±359.20)	0	0-5000	2.42	69.96
<b>Indirect cost</b>						
1.Travel expenses for the study participant and attendant	64229	146.64(±262.04)	100	0-2400	122.03	171.25
2. Loss of wages for the study participant and attendant	293470	670.02(±1058.3)	0	0-7500	570.63	769.41
Total	357699	816.66(±1083.81)	400	0-7500	714.8	918.4
<b>Grand Total</b>	<b>Rs. 373553</b>	852.80±1128.512				


\*Attendant loss of wages are taken for day of vaccination only (one day).

**Table 3: Percentage distribution of the type, place, adverse event after receiving COVID-19 vaccination**

Variable	N = 438	Percentage (%)
<b>Types of Vaccine</b>		
Covishield	398	90.9
Covaxin	40	9.1
<b>Reported Stress following vaccination</b>		
Yes	335	76.5
No	103	23.5
<b>AEFI within 48hrs</b>		
Yes	367	83.8
No	71	16.2
<b>AEFI *</b>		
Fever	265	60.50
Myalgia	161	36.8
Pain at the injection site	195	44.5
Headache	43	9.8
Malaise	13	3.0
<b>Receive any medication for Adverse Events</b>		

Yes	367	85.6
No	71	14.4
<b>Type of medicine</b>		
Antipyretic	325	74.2
Analgesic	32	7.3
Antihistamine	10	2.3
None	71	16.2

Majority of study participants received the vaccination at the 1<sup>st</sup> visit at the vaccination centre 426(97.3%), 2nd time 11 (2.5%), 3<sup>rd</sup> time 1 (0.2%). Participants were accompanied by a family member 281(64.1%), and used personal mode of transport 394 (90.0%). Mean duration of time to the health facility 14.74±14.20, Range (90-0)







		Co-efficient	constant					
Step 1 <sup>a</sup>	Age	-.006	.007	.832	1	.362	.994	.981 -1.07
	Constant	.221	.298	.550	1	.458	1.247	
Step 1 <sup>a</sup>	Gender (1)	.437	.194	5.085	1	.024	1.548	0.442 -0.944
	Constant	-.282	.145	3.752	1	.053	.755	
Step 1 <sup>a</sup>	Comorbidity	.229	.247	.855	1	.355	1.257	0.774 -2.401
	Constant	-.452	.460	.967	1	.325	.636	
Step 1 <sup>a</sup>	Type of vaccine	.761	.352	4.670	1	<b>.031</b>	<b>2.141</b>	<b>1.073 -4.24</b>
	Constant	-1.492	.683	4.778	1	.029	.225	
Step 1 <sup>a</sup>	Place of vaccination	1.452	.796	3.322	1	.068	4.271	0.892 -20.34
	Constant	-1.517	.814	3.475	1	.062	.219	
Step 1 <sup>a</sup>	Education	.290	.248	1.368	1	.242	1.337	0.94 -2.65
	Constant	-.563	.461	1.494	1	.222	.569	
Step 1 <sup>a</sup>	Occupation	.714	.202	12.521	1	<b>.000</b>	<b>2.043</b>	<b>1.37-3.035</b>
	Constant	-1.202	.345	12.164	1	.000	.300	
Step 1 <sup>a</sup>	Education of household	-.074	.240	.096	1	.756	.928	0.581 -1.45
	Constant	.097	.442	.048	1	.826	1.102	
Step 1 <sup>a</sup>	Occupation of head of household	21.198	15191.270	.000	1	.999	1607969059.351	0.000
	Constant	-42.401	30382.541	.000	1	.999	.000	
Step 1 <sup>a</sup>	Duration	.009	.007	1.618	1	.203	1.009	.995 -1.02
	Constant	-.163	.137	1.399	1	.237	.850	
Step 1 <sup>a</sup>	Reported stress following vaccination	.544	.230	5.598	1	<b>.018</b>	<b>1.723</b>	<b>1.098-2.703</b>
	Constant	-.998	.419	5.678	1	.017	.369	
Step 1 <sup>a</sup>	Adverse event within 48 hr of vaccination	.754	.272	7.695	1	<b>.006</b>	<b>2.125</b>	<b>1.248-3.62</b>
	Constant	-1.426	.513	7.741	1	.005	.240	
Step 1 <sup>a</sup>	Received any medication for side effect	.543	.266	4.171	1	<b>.041</b>	<b>1.721</b>	<b>1.022 -2.84</b>
	Constant	-1.031	.500	4.255	1	.039	.357	
a. Variable(s) entered on step 1: Gender, Comorbidity, Type of vaccine, Place of Vaccine, Education, Occupation, Education of household, Occupation of Household, Duration, Side effect, reported stress following vaccination, Received and medication for side effect								

To assess the factors associated with out of pocket expenditure in study participants, age, gender, co- morbidity, type of vaccine, place of vaccine, education of the study participant,



								Lower Bound	Upper Bound
1.00	Intercept	-4.374	1.788	5.986	1	.014			
	Age	-.022	.011	4.034	1	.045	.979	.958	.999
	Gender	-.516	.230	5.012	1	.025	.597	.380	.938
	Education	-.313	.096	10.530	1	.001	.731	.606	.884
	Occupation	.096	.072	1.743	1	.187	1.100	.955	1.268
	Education of head of household	-.027	.073	.132	1	.716	.974	.844	1.124
	Total income of household	.000	.000	.008	1	.931	1.000	1.000	1.000
	Comorbidity	.045	.291	.024	1	.877	1.046	.591	1.850
	Duration	.009	.008	1.236	1	.266	1.009	.993	1.024
	Type of vaccine	1.037	.379	7.481	1	<b>.006</b>	<b>2.820</b>	<b>1.342</b>	<b>5.928</b>
	Place of vaccination	1.643	.876	3.520	1	.061	5.172	.929	28.790
	Reported stress following vaccination	.183	.363	.255	1	.614	1.201	.590	2.446
	AEFI within 48hr of vaccination	.789	.514	2.360	1	.125	2.202	.804	6.028
	Received any medication for AEFI	-.200	.419	.228	1	.633	.819	.361	1.860
a. The reference category is: .00.									

The factors which were included in the bivariate logistic regression was included in the multivariate logistic regression and the factor type of vaccine P value 0.006, was highly significant, with Odds Ratio =2.820, 95% CI=1.342-5.928 and was associated with higher out of pocket expenditure and rest of the factors were not significant statistically.

## Discussion

The COVID-19 pandemic caused nearly unprecedented harm to many nations' lives, health, and economies. Since Vaccination is an effective measure to prevent against infectious diseases COVID-19 vaccination prevent the severity of the illness and have played a vital role in preventing the mortality.

Out-of-pocket expenditure is a major problem. The National Health Policy 2017<sup>12</sup> estimated that 7% of the Indian population is pushed into poverty each year because they are not able to afford the OOP costs.

In the current study majority of the study subjects utilized the public facility 97.7%, for COVID 19 vaccination, may be explained due to the study place which was in urban poor locality.

Under the National COVID Vaccination Programme, the Government Vaccination Centres provided free of cost to all the eligible beneficiaries. In the Private Vaccination Centres cost of vaccines was on higher side, so the Centre capped the maximum price, for Covishield 780 INR, Covaxin 1410 INR, Sputnik V 1145 INR in June 2021<sup>13</sup>.

In the current study cost of vaccine in government facility was 0 INR which implies successful implementation of COVID 19 vaccination drive in India. In order to pace the vaccination programme and individuals who can afford the government had made availability of vaccine in the private hospital, where average cost of vaccine in private was 1378.5 INR per person which was on a higher side.

According to this study higher mean out of pocket expenditure was incurred for indirect cost i.e., loss of wages 670.02 INR. This study is in contrast to observation study conducted on Yellow fever immunization<sup>14</sup> and Routine Immunization<sup>15</sup> where travel expenses cost was higher.

Study found out the higher mean out of pocket expenditure was for indirect cost loss of wages followed by travel expenses, this has to be lowered as this may act as reasons for vaccine hesitancy. The factors associated with higher OOPE was 2 times in type of vaccine, occupation of the study subject and adverse event within 48hrs.

To the best of our knowledge this is the only study calculated on out of pocket expenditure on COVID 19 vaccination in adults. Limitation of the study could be the recall bias of the study participants.

With less than a third of health expenditure covered by the government, the major burden of India's health costs falls on individual households, per the [National Health Account Estimates](#) . Household out-of-pocket expenditure on health made up for 58.7% of the total health expenditure, [One in five](#) Indians fall below the poverty line and more are pushed into poverty every year due to health expenses, according to World Bank data.

The central government's expanded Covid-19 vaccination procurement policy also allows private hospitals to purchase doses directly from manufacturers, and to set prices for consumers. Currently, both SII and Bharat Biotech are providing doses to private hospitals at higher rates than to state governments. SII set the rate of Covishield for private hospitals at Rs 600 per dose and Bharat Biotech set the rate at Rs 1,200. Given this policy, manufacturers have a financial incentive to divert more stocks towards private hospitals. The entire course of two doses for people getting vaccinated in private facilities is a minimum Rs 1,200- Rs 2,400, just for the doses. Private hospitals also add [charges](#) for administering the vaccines.

These rates are unaffordable for a large section of the Indian population. The monthly per capita income of an average four-member household was Rs 4,979 in October 2020, seven months after the Covid-19 nationwide lockdown was imposed – a 17% decrease from the level of Rs 5,989 in January 2020, per Azim Premji University's [State of Working Report](#)

[India 2021](#), published this month. The number of individuals who earn less than the national minimum wage threshold ([Rs 375 per day](#)) increased by 23 crore during the pandemic, said the report.

Our study revealed the most common adverse event was fever in 60.50%, myalgia in 36.8%, pain at the injection site 44.5%, headache in 9.8% and malaise in 3.0%. which was in contrast Study conducted in Bangladesh by Parvej<sup>16</sup> et al showed fever (36.05%), muscle pain (31.69%), pain in the injection site (30.67%), and headache (23.40%) can be due to different geographical location. Around 85.6% had received medication for the adverse events, which was in contrast to study conducted by Parvej et al<sup>16</sup> where only 37.65 had received medication. In the current study the most common medication received is antipyretic 74.2%, which is similar Jain<sup>17</sup> et al. Majority of the study subjects had hypertension 64.2%, where has study conducted on health workers<sup>17</sup> only 4.5% had hypertension.

### **Conclusion and Recommendations**

Majority of the study subjects utilized public facility. The higher mean out of pocket expenditure was for indirect cost loss of wages followed by travel expenses. However the factors associated with higher out of pocket expenditure was type of vaccine, occupation of the study subject, reported stress following vaccination, adverse event within 48hrs, received any medication for adverse event.

The out-of-pocket expenditure is one of the hidden expenditures which is not included in the vaccination cost during immunization. To conclude the COVID -19 vaccination has proved to have the out-of-pocket expenditure of considerable amount, which is in the form of area of residence, traveling cost, traveling distance, and indirectly loss of wages due to time spent in traveling, waiting, and process of vaccination. Through this study, we could conclude that it could be one of the reasons for lower vaccination coverage, and vaccine hesitancy can be

associated with this extra expenditure. The health providers are given allowances for vaccination services but still, policymakers should take 'out-of-pocket expenditure' of the families of vaccinee into consideration because it may lead to catastrophic health expenses shattering the economy of the recipient family. Our government has already started health insurance benefits for a large segment of the population, and out-of-pocket expenditure due to immunization should be included under that initiative. The traveling cost can be reduced by providing quality services in the periphery.

In a country like India where social security schemes are not universal, out of pocket expenditure for vaccination may bring financial stress to the family and maybe an important reason to delay or deny vaccination. Social and health insurance policies should cover immunization as it is an important preventive strategy to combat vaccine-preventable communicable diseases.

Reducing out of pocket expenditure can involve program and policy changes that make vaccinations more affordable. Changes could include paying for vaccination administration, providing new or expanded insurance coverage (copayments / co-insurance).

COVID 19 vaccines are safe and the adverse events are mild. All the adults have to be immunized to fight against the COVID- 19 deadly disease.

### **Acknowledgement**

Authors would like to thank Postgraduate Dr.Lavanya .K , MBBS interns Ambika, Anjaly K Prakash, Anusha G V, Ashwini A, Bhoomika Choudary, Bhomika M O and Medical social workers Akshay Kumar, Shivaprasad and Durgesh for the support rendered for the smooth conduction of study. Authors are grateful for the study participants.

---



**Ethical approval:** The study was approved by the Institutional Ethical Committee, Akash Institute of Medical Sciences and Research Centre, Bengaluru, India.

**Conflict of interest:** None declared

**Funding:** No funding sources.

## References

1. Ministry of Health & Family Welfare. National Health Accounts Estimates for India 2017-2018. Available from [https://main.mohfw.gov.in/sites/default/files/FINAL%20National%20Health%20Accounts%202017-18\\_28102021.pdf](https://main.mohfw.gov.in/sites/default/files/FINAL%20National%20Health%20Accounts%202017-18_28102021.pdf). [Last Accessed on 31 December 2021]
2. Kastor A, Mohanty SK: Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: do Indian households face distress health financing? PLoS One. 2018, 13:1-18.
3. The Wire. Health. Available from: <https://thewire.in/health/health-ministry-out-of-pocket-expenses-drop-catch-hospital> . [Last Accessed on 22 December 2021].
4. Vikaspeda. Report on National Health Accounts Estimates for India for 2017- 18. Available from: <https://vikaspedia.in/news/report-of-national-health-account-estimates-for-india-for-2017-18-released>. [Last Accessed on 27 December 2021].
5. World Health Organization. More than half a billion people pushed or pushed further into extreme poverty due to health care costs. Available from <https://www.who.int/news/item/12-12-2021-more-than-half-a-billion-people-pushed-or-pushed-further-into-extreme-poverty-due-to-health-care-costs>. [Last Accessed on 16 December 2021].
6. Pandey A, Ploubidis GB, Clarke L, Dandona L: Trends in catastrophic health expenditure in India: 1993 to 2014. Bull World Health Organ. 2018, 96:18-28.

7. Mathur M, Mathur N, Khan N et al. Predictors of 'Out-of-Pocket Expenditure' on Routine Immunization of Under-Five Children: A Regression Analysis. *Cureus* 12(12): e11859. DOI 10.7759/cureus.11859.
8. Ministry of Health and Family Welfare. Vaccine Registration. Available at: [https://www.mohfw.gov.in/covid\\_vaccination/vaccination/faqs.html](https://www.mohfw.gov.in/covid_vaccination/vaccination/faqs.html). [Last Accessed on 27 November 2021].
9. COVID 19 Information Portal. Government of Karnataka. Available at: <https://covid19.karnataka.gov.in/english>. [Last Accessed on 26 November 2021].
10. World Health Organization. Corona virus disease (COVID-19). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19>. [Last Accessed on 11 Nov 2021].
11. Government of Karnataka. COVID 19 Information Portal. Available at: [https://covid19.karnataka.gov.in/govt\\_bulletin/en](https://covid19.karnataka.gov.in/govt_bulletin/en). [Last Accessed on 15 December 2021].
12. Ministry of Health and Family Welfare. National Health Policy 2017. New Delhi: Government of India. Available from: [https://www.nhp.gov.in/nhpfiles/national\\_health\\_policy\\_2017.pdf](https://www.nhp.gov.in/nhpfiles/national_health_policy_2017.pdf). [Last Accessed on 24 December 2021].
13. Ministry of Health & Family Welfare. Revised Guidelines for Implementation of National COVID vaccination Programme. Available from: <https://www.mohfw.gov.in/pdf/RevisedVaccinationGuidelines.pdf>. [Last Accessed on 6 January 2022].
14. Dan A, Khandare K, Gaikwad P et al. Out of pocket expenditure for yellow fever vaccination in India. *Int J Health Sci Res.* 2017; 7(8):13-18.

15. Singh N, Thakur S. Estimating the Out of Pocket Expenditure for Parents coming in an Immunization Clinic of Ghaziabad. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), 19(2), 2020, pp. 01-04.
16. Parvej MI, Sultana S, Tabassum M, Mannan SE, Ahmed F. Determinants of COVID-19 vaccine acceptance and encountered side-effects among the vaccinated in Bangladesh. Asian Pac J Trop Med 2021; 14(8): 341-349.
17. Jain T, Eashwar VMA, Mohan Y, Kumar D, Queen Nesan G Shiny Chrism, Maiya GR. A Longitudinal Study on Adverse Events Following COVID-19 Vaccination among Healthcare Workers in a Tertiary Care Hospital in Tiruvallur District, Tamil Nadu. Natl J Community Med 2021; 12(9):284-289.